Anika Therapeutics, Inc.
ANIK
Surgical & Medical Instruments & Apparatus
Mkt Cap
$363.9MPE
-4.74Debt
-Cash
$68.63MEV
-FCF
-$4.142MP/E Ratio
-4.74Debt
-Cash
$68.63MEV
-FCF
-$4.142MCharts data: {"Earnings":[{"time":"2014-12-30","value":38319479},{"time":"2015-12-30","value":30758000},{"time":"2016-12-30","value":32547000},{"time":"2017-12-30","value":31816000},{"time":"2018-12-30","value":18722000},{"time":"2019-12-30","value":27193000},{"time":"2020-12-30","value":-23982000},{"time":"2021-12-30","value":4134000},{"time":"2022-12-30","value":-14859000},{"time":"2023-12-30","value":-82667000}],"Sales":[{"time":"2014-12-30","value":105594839},{"time":"2015-12-30","value":92999000},{"time":"2016-12-30","value":103379000},{"time":"2017-12-30","value":113420000},{"time":"2018-12-30","value":105555000},{"time":"2019-12-30","value":114610000},{"time":"2020-12-30","value":130457000},{"time":"2021-12-30","value":147794000},{"time":"2022-12-30","value":156236000},{"time":"2023-12-30","value":166662000}],"Net Margins":[{"time":"2014-12-30","value":0.36289158980582376},{"time":"2015-12-30","value":0.33073473908321593},{"time":"2016-12-30","value":0.314831832383753},{"time":"2017-12-30","value":0.2805149003703051},{"time":"2018-12-30","value":0.17736724930131212},{"time":"2019-12-30","value":0.23726550911787803},{"time":"2020-12-30","value":-0.1838306875062281},{"time":"2021-12-30","value":0.02797136554934571},{"time":"2022-12-30","value":-0.09510612150848716},{"time":"2023-12-30","value":-0.49601588844487643}],"Assets":[{"time":"2014-12-30","value":193996376},{"time":"2015-12-30","value":235748000},{"time":"2016-12-30","value":240246000},{"time":"2017-12-30","value":282617000},{"time":"2018-12-30","value":278993000},{"time":"2019-12-30","value":330710000},{"time":"2020-12-30","value":365605000},{"time":"2021-12-30","value":347535000},{"time":"2022-12-30","value":349128000},{"time":"2023-12-30","value":270632000}],"Stockholders Equity":[{"time":"2014-12-30","value":178097097},{"time":"2015-12-30","value":210848000},{"time":"2016-12-30","value":222773000},{"time":"2017-12-30","value":263491000},{"time":"2018-12-30","value":263612000},{"time":"2019-12-30","value":288378000},{"time":"2020-12-30","value":272400000},{"time":"2021-12-30","value":287085000},{"time":"2022-12-30","value":285563000},{"time":"2023-12-30","value":212265000}],"ROE":[{"time":"2014-12-30","value":0.21516060421804628},{"time":"2015-12-30","value":0.14587759902868416},{"time":"2016-12-30","value":0.14609939265530383},{"time":"2017-12-30","value":0.12074795723573101},{"time":"2018-12-30","value":0.07102104608287939},{"time":"2019-12-30","value":0.09429637489683679},{"time":"2020-12-30","value":-0.08803964757709251},{"time":"2021-12-30","value":0.014399916401065886},{"time":"2022-12-30","value":-0.05203405203055018},{"time":"2023-12-30","value":-0.38945186441476454}],"ROA":[{"time":"2014-12-30","value":0.31704211319906306},{"time":"2015-12-30","value":0.20468466328452414},{"time":"2016-12-30","value":0.21174129850236842},{"time":"2017-12-30","value":0.1634791962266955},{"time":"2018-12-30","value":0.0831812984555168},{"time":"2019-12-30","value":0.10922258171812162},{"time":"2020-12-30","value":-0.07746611780473461},{"time":"2021-12-30","value":0.007524422000661804},{"time":"2022-12-30","value":-0.05369377420315758},{"time":"2023-12-30","value":-0.31528791864967926}]}
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Sector
![GKOS Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>GKOS</text></svg>){kind=small}
![GMED Logo](data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' width='18' height='18'><defs><linearGradient id="a" x1="3.349" x2="21.904" y1="3.122" y2="24.434" gradientUnits="userSpaceOnUse"><stop stop-color="%231A1E21"/><stop offset="1" stop-color="%2306060A"/></linearGradient></defs><path fill="url(%23a)" d="M0 0h18v18H0z"/><text x='50%' y='52%' dominant-baseline='middle' text-anchor='middle' font-size='5' font-family='sans-serif' fill='gray'>GMED</text></svg>){kind=small}
In the chart Earnings are multiplied by this value.
Earnings Growth -16%
Earnings Stability -7.6%
Competitiveness and MOAT
High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 33% | 31% | 28% | 18% | 24% | -18% | 2.8% | -9.5% | -50% | -45% |
| ROA | 20% | 21% | 16% | 8.3% | 11% | -7.7% | 0.75% | -5.4% | -32% | -29% |
| ROE | 15% | 15% | 12% | 7.1% | 9.4% | -8.8% | 1.4% | -5.2% | -39% | -37% |
What is the average Net Margin?
The average Net Margin over the past 5 years is -5.54%.
What is the trend of Net Margin?
The trend of Net Margin over the past 5 years is -11.86%.
What is the average Return on Assets (ROA)?
The average ROA over the past 5 years is -4.11%.
What is the trend of Return on Assets (ROA)?
The trend of ROA over the past 5 years is -6.85%.
What is the average Return on Equity (ROE)?
The average ROE over the past 5 years is -5.83%.
What is the trend of Return on Equity (ROE)?
The trend of ROE over the past 5 years is -7.54%.
Safety & Stabiliy
Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.
| Years | 12-2015 | 12-2016 | 12-2017 | 12-2018 | 12-2019 | 12-2020 | 12-2021 | 12-2022 | 12-2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt FCF | - | - | - | - | 0.00 | - | - | - | - | - |
| Debt Equity | - | - | - | - | 0.00 | - | - | - | - | - |
| MIN | ||||||||||
| Graham Stability | - | - | 94% | 59% | 98% | -93% | 57% | -610% | - | -610% |
What is the Debt/FCF?
The Debt/FCF trailing twelve month is -.
What is the trend of Debt/FCF?
The trend of Debt/FCF over the past 5 years is -.
What is the Graham’s Stability?
Graham’s Stability measure stands at -6.07.
Growth
Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.
| Years | 12-2016 | 12-2018 | 12-2020 | 12-2022 | Trend |
|---|---|---|---|---|---|
| Revenue | 7.1% | 9.6% | 8.5% | 6.7% | 1.4% |
| Net Income | - | - | - | - | 8.3% |
| Stockholders Equity | -0.69% | -4.2% | -8% | -26% | -3.8% |
| FCF | - | - | - | - | -13% |
What is the 5 year Revenue CAGR?
The Revenue CAGR over the past 5 years is +9.56%.
What is the trend of Revenue growth?
The trend of Revenue growth rate over the past 5 years is +1.43%.
What is the 5 year Earnings CAGR?
The Earnings CAGR over the past 5 years is -.
What is the trend of Earnings growth?
The trend of Earnings growth rate over the past 5 years is +8.3%.
What is the 5 year Equity CAGR?
The Equity CAGR over the past 5 years is -4.24%.
What is the trend of Equity growth?
The trend of Equity growth rate over the past 5 years is -3.77%.
What is the 5 year FCF CAGR?
The FCF CAGR over the past 5 years is -.
What is the trend of FCF growth?
The trend of FCF growth rate over the past 5 years is -12.81%.